Novartis
NEWS
It was a fairly busy week for clinical trial announcements, with some important and interesting news about COVID-19 treatments and vaccines, as well as numerous stories about non-COVID-19 studies.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 18, 2020.
The manufacturing site will expand BioNTech’s COVID-19 vaccine production capacity by up to 750 million doses per year, or over 60 million doses per month, once fully operational, the company said.
It was a busy week for clinical trial updates. Here’s a look.
It was a busy week for both COVID-19-related clinical trial news and the rest of the industry. Here’s a look.
Boston Pharmaceuticals licensed the drug candidate BOS-580, an injectable, genetically engineered variant of human FGF21.
As August wraps up, there were still clinical trial announcements, although fewer than earlier this summer. Here’s a look.
Specifically, the trial of Spartalizumab did not meet the primary endpoint of investigator-assessed progression-free survival.
The U.S. Food and Drug Administration (FDA) approved Novartis’ Kesimpta (ofatumumab) for relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
JOBS
IN THE PRESS